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Host-directed therapy is a strategy to
improve the lengthy treatment of
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binds to several TB drugs, resulting in
altered host defense and drug
metabolism. Modulation of the AhR in
infected zebrafish embryos leads to
improved treatment efficacy.
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2Department for Structural Infection Biology, Center for Structural Systems Biology, Notkestraße 85, Hamburg 22607, Germany
3Institute of Biology, Leiden University, Sylviusweg 72, Leiden 2333, the Netherlands
4Leibniz-Forschungsinstitut f€ur Molekulare Pharmakologie, Robert-Rössle-Strasse 10, Berlin 13125, Germany
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Antimicrobial resistance in tuberculosis (TB) is a pub-
lic health threat of global dimension, worsened by
increasing drug resistance. Host-directed therapy
(HDT) is an emerging concept currently explored as
an adjunct therapeutic strategy for TB. One potential
host target is the ligand-activated transcription fac-
tor aryl hydrocarbon receptor (AhR), which binds
TB virulence factors and controls antibacterial re-
sponses. Here, we demonstrate that in the context
of therapy, the AhR binds several TB drugs, including
front line drugs rifampicin (RIF) and rifabutin (RFB),
resulting in altered host defense and drug meta-
bolism. AhR sensing of TB drugs modulates host de-
fense mechanisms, notably impairs phagocytosis,
and increases TB drug metabolism. Targeting AhR
in vivo with a small-molecule inhibitor increases
RFB-treatment efficacy. Thus, the AhR markedly im-
pacts TB outcome by affecting both host defense
and drug metabolism. As a corollary, we propose
the AhR as a potential target for HDT in TB in adjunct
to canonical chemotherapy.
INTRODUCTION
The aryl hydrocarbon receptor (AhR) is an evolutionary highly
conserved ligand-dependent transcription factor that functions
as a cellular sensor of both extrinsic and intrinsic chemical sig-
nals (Kawajiri and Fujii-Kuriyama, 2017). AhR ligands are diverse
and encompass environmental toxins, cell- andmicrobe-derived
metabolites, and dietary products (Hubbard et al., 2015). Ligand
binding to the AhR, induces transcription of target genes238 Cell Host & Microbe 27, 238–248, February 12, 2020 ª 2019 Elseinvolved in xenobiotic metabolism, cell homeostasis, embryonic
development, and immunity (Gutiérrez-Vázquez and Quintana,
2018). Previously, our group described AhR sensing of the naph-
thoquinone phthiocol (Pht) produced by Mycobacterium tuber-
culosis (Mtb), the causative agent of tuberculosis (TB) in humans,
and its importance in host defense against Mtb (Moura-Alves
et al., 2014). TB remains the leading cause of death by a single
infectious agent, and the emergence of antimicrobial resistance
(AMR) in TB has led to a public health crisis (World Health Orga-
nization, 2019). Non-compliance and incorrect use of TB drugs
have contributed to the emergence of multidrug-resistant
(MDR) and extensively drug-resistant (XDR) Mtb strains,
rendering several first-line drugs ineffective. AMR requires pro-
longed and more expensive chemotherapy regimens, often
with severe adverse events for patients and creating an enor-
mous economic burden (World Health Organization, 2019).
Host-directed therapy (HDT) is an emerging concept currently
explored as adjunct strategy for TB treatment to counteract
AMR (Kolloli and Subbian, 2017; Kaufmann et al., 2018). Given
that the AhR is positioned at the center of xenobiotic metabolism
regulation and host defense, the AhR represents a promising
target for HDT in TB. Here, we explore whether AhR not only
modulates infection (Moura-Alves et al., 2014) but also drug ther-
apy. We demonstrate that (1) the AhR binds and senses several
first- and second-line TB drugs, (2) AhR modulation by TB drugs
inhibits macrophage phagocytosis, (3) the AhR is involved in the
metabolism of rifabutin (RFB), and (4) inhibition of the AhR by a
specific small-molecule inhibitor enhances RFB-mediated anti-
microbial activity. Thus, we propose the AhR as a candidate
target for future HDT in adjunct to canonical TB drug treatment.
RESULTS
TB Drugs Modulate AhR Signaling
Using a previously established macrophage AhR luciferase re-






Figure 1. RFB and RIF Modulate AhR Signaling In Vitro
(A and B) Luciferase activity of macrophage (THP-1) luciferase AhR reporter cells upon 4 h stimulation with RFB (A) or RIF or Pht (B).
(C) Pht-RIF competition assay: first pre-incubation with increasing concentrations of RIF for 1 h, followed by 3 h stimulation together with 50 mM Pht or Pht alone
as control.
(D) Gene-expression analysis of AhR-dependent genes in THP-1 macrophages upon stimulation with Pht or RFB for 4 h.
(E and F) Hepatic CYP1A1 enzymatic activity (Hepa-1c1c7) upon stimulation with increasing concentrations of RFB and (E) TCDD over time or (F) Pht after 24 h.
(G and H) Hepatic CYP1A1 enzymatic activity (Hepa-1c1c7) upon stimulation with (G) Pht or (H) increasing concentrations of RIF.
(H) Pht-RIF competition assay: first pre-incubation with increasing concentrations of RIF for 1 h, followed by stimulation together with 50 mM Pht or Pht alone
for 3 h.
(A–C and F) 1 representative of n = 4 independent experiments.
(D, E, G, and H) 1 representative of n = 3 independent experiments.
(A–D and F–H) Mean ± SD shown.
(D) Unpaired t test.
(E) Mean only shown. **p % 0.01, ***p % 0.001, ****p % 0.0001.
See also Figure S1 and S2.
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Table 1. List of TB Drugs Tested in the AhR Reporter Assay
Drug Abbreviation AhR Modulation
Group 1: First-Line Oral TB Drugs
Ethambutol EMB No effect
Isoniazid INH No effect




Group 2: Injectable TB Drugs
Amikacin AMK No effect
Kanamycin KAN No effect









p-Aminosalicyclic acid PAA No effect
Group 5: Currently Not Included in Core MDR-TB Regimen
Thiacetazone THZ Inhibitorwe tested diverse TB drugs in clinical use for their potential to
modulate AhR signaling. Of note, TB drug concentrations used
in our study conform with drug concentrations used in another
large European study testing different animal models (PreDiCT-
TB) (Kaufmann et al., 2015). Several TB drugs modulated AhR
in reporter cells, similar to the known AhR activators 2,3,7,8-tet-
rachlorodibenzo-p-dioxin (TCDD) (Nebert et al., 1972) and Mtb-
derived pigment Pht (Moura-Alves et al., 2014) (Figures 1A–1C,
S1A, and S1B). Among the tested first-line TB drugs (group 1),
we identified RFB as potent activator of the AhR (Figures 1A
and S1C). Stimulation with RFB, or itsmajor metabolite 25-O-de-
acetylrifabutin (25-O-DRFB), resulted in dose-dependent AhR
activation (Figure S1C). Among newly approved drugs for the
treatment of drug-resistant TB (groups 2–5), we identified beda-
quiline (BDQ) and linezolid (LZD) as activators of the AhR (Figures
S1D and S1E). Exposure to the specific synthetic AhR inhibitor
CH-223191 (Kim et al., 2006) blocked the induction of luciferase
activity upon stimulation with TCDD, Pht (Figures S1F and S1G),
RFB, BDQ, and LZD (Figures S1H–S1J). Consistently, AhR
knockdown showed a similar phenotype (Figures S1K–S1M).
Several TB drugs did not activate the AhR but significantly
decreased Pht-induced AhR activation when administered prior
to stimulation with Pht (Figures 1B, 1C, and S1N–S1S). Pre-incu-
bation with the first-line TB drugs rifampicin (RIF) and rifapentine
(RPT) markedly decreased Pht-induced AhR activation (Figures
1B, 1C, and S1N). Similarly, stimulation with TB drugs of groups
3–5—including enrofloxacin (ERF), moxifloxacin (MXF), ethion-
amide (ETA), clofazimine (CFZ), and thiacetazone (THZ)—also
decreased Pht-induced AhR activation (Figures S1O–S1S).
Taken together, using THP-1 AhR reporter, we identified several240 Cell Host & Microbe 27, 238–248, February 12, 2020first- and second-line TB drugs as potent modulators of the ca-
nonical AhR pathway (Table 1).
Both RFB and RIF are key first-line TB drugs (World Health Or-
ganization, 2016). Based on the observed opposing effects on
AhR modulation, we further focused on the characterization of
RFB- and RIF-mediated effects on the AhR as examples of TB
drugs with AhR modulatory capacities. To exclude that AhR
modulation mediated by RFB and RIF was because of impaired
cell viability, we monitored lactate dehydrogenase release (LDH)
and caspase-3/7 activity of reporter macrophages. No signifi-
cant differences were observed under the conditions tested (Fig-
ures S2A and S2B). Similar to Pht, RFB induced the expression
of AhR-dependent genes (CYP1A1, CYP1B1, and AHRR) in
THP-1 macrophages, whereas AHR expression itself remained
unaltered (Figures 1D and S2C). Consistently, in a murine hepa-
tocyte cell line (Hepa-1c1c7), RFB activated the AhR in a dose-
dependent manner (Figure S2D). Recently, it was reported that
AhR activity can be modulated indirectly via dysregulation of
CYP1A1 (Wincent et al., 2012). To evaluate whether inhibition
of CYP1A1 by RFB activates the AhR indirectly, we measured
CYP1A1 enzymatic activity. Stimulation of Hepa-1c1c7 cells
with RFB led to a dose-dependent increase in enzymatic
CYP1A1 activity, similar to stimulation with Pht or TCDD (Figures
1E and 1F). Thus, we exclude indirect AhR activation by CYP1A1
inhibition. In contrast, RIF stimulation of Hepa-1c1c7 cells did
not induce CYP1A1 activity but profoundly inhibited Pht-induced
CYP1A1 activity (Figures 1G and 1H). Our data suggest that both
RFB and RIF are modulators of the canonical AhR pathway with
opposing effects on AhR signaling.
RFB and RIF Bind to the AhR
To evaluate binding of TB drugs to the AhR, we tested ligand
binding to a purified AhR protein by microscale thermophoresis
(MST). MST allows measurement of protein-ligand interactions
based on temperature-induced changes in the fluorescence of
a target of interest (here, AhR) and a non-fluorescent ligand
(Seidel et al., 2013). We confirmed binding of RIF (Kd 11.3 mM),
RFB (Kd 16.1 mM), and the RFB metabolite 25-O-DRFB (approx-
imately Kd 24.5 mM) to the AhR (Figures 2A–2C, S3A, and S3B).
Importantly, binding to the AhR nuclear translocator (Arnt) was
not observed, indicating the specificity of ligand binding to the
AhR under the conditions tested. As a control, we tested binding
of isoniazid (INH), another first-line TB drug, in which we
observed no AhR modulation in the reporter assay (Table 1).
Consistently, we did not detect binding of INH to the AhR (Fig-
ures S3A and S3C). We conclude that the first-line TB drugs
RIF and RFB, as well as its metabolite 25-O-DRFB, bind to and
modulate AhR activity, rendering anti-mycobacterial drugs a
class of AhR ligands.
The atomic structure of the AhR ligand binding domain remains
unknown. Therefore, despite being only predictive, computa-
tional-based molecular modeling studies are widely used to pre-
dict how different ligands bind to and modulate AhR functions
(Pohjanvirta, 2011; Moura-Alves et al., 2014; Corrada et al.,
2017; Mahiout et al., 2018). We applied molecular modeling and
in silico docking to determine how RFB and RIF fit into the pro-
posed binding pocket of the AhR (Moura-Alves et al., 2014).
Despite structural similarities of the cyclic part between RFB
and RIF, parts of their backbone conformations, orientations,
Figure 2. AhR Binding of TB Drugs
(A and B) AhR-binding studies of (A) RFB and (B) RIF to the AhR protein complex (AhR-Arnt) or Arnt alone using MST. Median ± SD of triplicates shown.
(C) Chemical structures of RFB and RIF.
(D) Best scoring ligand docking poses for RFB (left, magenta) and RIF (right, yellow) in the in silico model of the hAhR-PasB. H-bonds are depicted as yellow
dotted lines; different conformations of the outward-oriented residues F295, Y322, and H337 are depicted in pale wheat; outward-oriented residues on the
backside of the b sheet A, I, J (Ile286, Gln364, and Arg384) that are able to interact with PasA of Arnt are depicted in pale blue.
See also Figure S3 and Table S1.and size of the substituents differ (Figure 2C). While RFB and RIF
do not resemble prototypic AhR ligands (Figures 2C and S3D),
molecular modeling and in silico docking resulted in putative
fitting into the ligand binding pocket of the AhR-PasB model,
with only few possible configurations (calculated DG binding:
RFB = 130.16 kcal/mol and RIF = 125.21 kcal/mol
and 118.66 kcal/mol) (Table S1). Interestingly, docking of RFB
and RIF into the AhR binding pocket resulted in different orienta-
tions, suggesting dissimilar interaction profiles (Figure 2D; Table
S1).Within the AhR-PasB ligandbinding pocket, RFB formedmul-
tiple hydrogen bonds with the side chains of Thr289, His291,
Ser365, and Gln383, altering the existing H-bond network be-
tween these residues. Such rearrangements influence the struc-
tural adjustment, especially the N- and C-terminal endings of
particular b strands (segments A, I, and J) of the b sheet and the
AB-loop, which leads to a constrained backbone conformation
at two locations: (1) at theAB-loop aspart of the interface between
the AhR and the PasB of Arnt (Corrada et al., 2017;,Corrada et al.,
2016), comprised of Phe295 (AB-loop), Tyr322 (helix E), and
His337 (helix F) (Figures 2D, S3E, and S3F); and (2) at the interface
between the AhR and the PasA of Arnt (Figure S3E) that is formed
by outward-oriented residues on the N-terminal end of b strand A
(Ile286) and/or on the backside of b strands I and J (Gln364 and
Arg384) (Figure 2D). Compared with RFB, both RIF and the spe-
cific AhR inhibitor CH-223191 (Figures 2D, S3D, and S3F; TableS1) formed considerably less H-bonds to residues on the b
strands A, I, and J. Such differences in RFB, RIF, and
CH-223191 binding to the AhR lead to opposing conformational
influences on the two interaction positions, potentially impacting
AhR activation.
Modulation of the AhR Impairs Macrophage
Phagocytosis
We further evaluated potential effects of ligand-induced AhR
modulation in the context of infection and TB drug therapy. We
assessed whether the AhR could play a role in macrophage
phagocytosis of Mtb. Inhibition of the AhR by CH-223191 in
THP-1 macrophages reduced the uptake of Mtb H37Rv (Fig-
ure 3A). Likewise, AhR-inhibition decreased uptake of fluores-
cently labeled Mtb H37Rv, paralleled by a reduction in the
proportion of Mtb-harboring cells (Figures 3B, 3C, and S4A).
Exposure to CH-223191 did not affect Mtb or macrophage
viability (Figures S4B–S4F). Consistently, knockdown of the
AhR in THP-1 macrophages likewise resulted in reduced uptake
of Mtb H37Rv (Figure 3D). To further characterize the role of the
AhR in phagocytosis, we used the fungal glucan zymosan conju-
gated to a pH-sensitive dye (pHrodo), which allows visualization
of phagosomal uptake and acidification (Queval et al., 2017).
Consistent with Mtb phagocytosis, the proportion of zymosan-
containing macrophages and the rate of internalization wereCell Host & Microbe 27, 238–248, February 12, 2020 241
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Figure 3. Modulation of Phagocytosis by AhR
(A–D) Uptake of Mtb multiplicity of infection (MOI) of 10 by AhR proficient or deficient (12 mM CH-223191 pre-treatment for 2 h or shRNA knockdown) THP-1
macrophages after 4 h, measured by (A and D) CFU (Mtb H37Rv) or (B and C) microscopy (Mtb-GFP H37Rv).
(E–G) Phagocytosis of zymosan-pHrodo by macrophages (RAW264.7) 2 h after pre-incubation with 12 mMCH-223191 or dimethyl sulfoxide (DMSO; solvent) for
2 h. (E) Percentage of zymosan-pHrodo positive cells, (F) rate of zymosan-pHrodo internalization, and (G) average intensity of internalized pHrodo.
(H–M) Phagocytosis of zymosan-pHrodo bymacrophages (THP-1) 2 h after pre-incubation with (H–J) RIF and (K–M) TCDD or RFB for 2 h. (H and K) Percentage of
zymosan-pHrodo positive cells, (I and L) rate of internalization of zymosan-pHrodo, and (J and M) average intensity of internalized pHrodo.
(N) Uptake of RIF-resistant Mtb MOI of 10 by THP-1 macrophages pre-treated for 2 h with 10 mM RIF or DMSO (solvent) after 4 h, measured by CFU.
(A and D) 1 representative of n = 2 independent experiments.
(B, C, and E–M) 1 representative of n = 3 independent experiments.
(legend continued on next page)
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Figure 4. AhR Inhibition in Human Hepatocytes Affects RFB Avail-
ability
(A) Percentage of RFB recovery from HepaRG culture supernatants over time
compared with no cells control for each time point. 1 representative of n = 3
independent experiments. Mean ± SD shown.
(B) Percentage of RFB recovery from HepaRG culture supernatants in the
presence or absence of CH-223191 after 48 h compared with the input and
normalized to no cells control. Pooled data from n = 2 independent experi-
ments. Mean ± SEM shown.
See also Figure S5.decreased upon AhR inhibition (Figures 3E and 3F). AhR inhibi-
tion also reduced the pHrodo fluorescence intensity of internal-
ized zymosan, indicating an AhR-dependent impact on macro-
phage phagosomal acidification (Figure 3G). Our data suggest
a role for the AhR in macrophage phagocytosis of Mtb and the
fungal glucan zymosan.
We extended our investigation of AhR-dependent phagocy-
tosis to other AhR ligands, including TB drugs. The AhR antago-
nist RIF potently inhibited uptake of zymosan-pHrodo by macro-
phages, indicated by reduced numbers of zymosan-containing
cells and the rate of internalization (Figures 3H and 3I). Moreover,
RIF impaired phagosomal acidification, similar to the synthetic
AhR inhibitor (Figures 3G and 3J). Notably, a similar phenotype
was observed upon exposure to the AhR agonists TCDD and
RFB (Figures 3K–3M). In contrast, INH, which neither binds nor
modulates AhR, did not impair phagocytosis (Figures S4G–
S4I). To further explore RIF-elicited effects on the AhR in the
absence of a direct antimicrobial effect on Mtb, we took advan-
tage of a RIF-resistant Mtb strain. Similar to what we observed
for zymosan-pHrodo, RIF treatment of macrophages reduced
uptake of the RIF-resistant patient isolate (Figure 3N). RIF resis-
tance was confirmed by monitoring cultural growth in the pres-
ence or absence of RIF in comparison with a drug-sensitive
Mtb patient isolate (Figures S4J and S4K), and by next genera-
tion sequencing and drug-susceptibility testing (Table S2). We
conclude that ligand-induced AhR modulation impairs macro-(N) Pooled data from n = 2 independent experiments.
Shown as (A and D) mean ± S.D., (B, C, E, H, and K) boxplot with Tukey whisker
(A–M) Unpaired t test. *p % 0.05, **p % 0.01, ****p % 0.0001.
(N) Mann-Whitney test. *p % 0.05.
See also Figure S4 and Table S2.phage phagocytosis. Moreover, we identified a yet-unknown
host-directed effect of the TB drugs RIF and RFB on macro-
phage phagocytosis.
AhR Is Involved in Metabolism of RFB
Pharmacokinetic and pharmacodynamic factors markedly
influence drug availability and efficacy, which are essential for
successful treatment (Rowland and Tozer, 2011). The AhR is a
central regulator of xenobiotic metabolism (Stockinger et al.,
2014). Hence, we evaluated whether the AhR is involved in the
metabolism of RFB. We made use of the human hepatic stem
cell line HepaRG, which has AhR expression levels reported to
be comparable with primary human hepatocytes (Guillouzo
et al., 2007). Moreover, HepaRG cells expressmultiple functional
phase 1 and 2 drug metabolizing enzymes, rendering them suit-
able for studies on xenobiotic metabolism (Guillouzo et al.,
2007). We monitored RFB clearance from cell culture superna-
tants using ultra-performance liquid chromatography (UPLC).
We observed continuous elimination of RFB from HepaRG cell
cultures (Figure 4A). Strikingly, RFB recovery from supernatants
of AhR-inhibited cells was higher when compared with solvent
controls (Figure 4B). Importantly, treatment of HepaRG cells
with CH-223191 and/or RFB did not impair cell viability at the
concentrations used (Figures S5A and S5B). Our data suggest
that the AhR is involved in hepatic metabolism of RFB and that
inhibiting the AhR reduces RFB metabolism, ultimately affecting
its availability.
In Vivo Modulation of AhR by TB Drugs
The zebrafish (Danio rerio) has emerged as valuable animal
model to study toxicology (Roper and Tanguay, 2018) and the
mechanisms of disease, including TB (Van Leeuwen et al.,
2015). Increasingly, zebrafish have been harnessed for high-
throughput in vivo screenings of novel drug candidates, such
as antimicrobials (Zhong and Lin, 2011; Dalton et al., 2017).
We used zebrafish to validate our in vitro findings. Similar to
what we observed in cell lines, exposure of zebrafish embryos
to RFB induced AhR downstream target genes, such as ahrra
(Evans et al., 2005), ahrrb (Evans et al., 2005), and cyp1a
(Prasch et al., 2003), in an AhR-dependent manner (Figure 5A).
Furthermore, in vivo EROD assays detected increased Cyp1a
enzymatic activity upon RFB exposure, similar to that induced
by Pht (Figure 5B). CH-223191 blocked cyp1a gene expression
(Figure 5A) and induction of Cyp1a enzymatic activity (Fig-
ure 5C). Exposure of zebrafish embryos to increasing concen-
trations of RIF did not induce Cyp1a activity (Figure 5D);
instead, RIF potently inhibited TCDD-induced Cyp1a enzy-
matic activity (Figure 5E). We did not detect toxicity in zebrafish
for any of the ligands and conditions tested (Figures S6A and
S6B). To evaluate whether the AhR also plays a role in RFB
metabolism in vivo, we exposed zebrafish embryos to RFB in
the water and collected samples at 4 days post-exposure. Ins, (F, G, I, J, L, and M) scatter dot plot with mean, (N) mean ± SEM.




Figure 5. AhR Modulation by RFB and RIF In Vivo
(A) Gene-expression analysis of AhR-target genes in 2 days post-fertilization (dpf) zebrafish embryos upon 4 h of stimulation with RFB, in the presence or absence
of CH-223191. Triplicates, each consisting of 12 zebrafish embryos pooled. Mean ± SD shown.
(B–E)Cyp1a enzymatic activity (EROD) in 2 dpf embryos treated for 4hwith (B) Pht or increasing concentrations of RFB, (C) with RFB in the presence or absence of
CH-223191, (D) with TCDD or increasing concentrations of RIF, and (E) with TCDD in the presence or absence of RIF. Each data point depicts an individual
zebrafish embryo. Mean ± SEM shown.
(F) Recovery of RFB from the water of zebrafish embryos after 4 days of exposure to 5 mM RFB in the presence of 10 mM CH-223191 compared with DMSO
(solvent) control.
(A–E) 1 representative of n = 3 independent experiments.
(F) Pooled data from n = 2 independent experiments. Mean ± SEM shown.
(A-F) Unpaired t test. ns (not significant), *p % 0.05, **p % 0.01, ***p % 0.01 ****p % 0.0001.
See also Figure S6.agreement with results from human hepatocyte cultures (Fig-
ure 4B), AhR inhibition in zebrafish resulted in higher RFB re-
covery compared with controls (Figure 5F). Altogether, we
demonstrate that in vivo exposure of zebrafish embryos to TB
drugs, such as RFB and RIF, modulate AhR downstream re-
sponses including the regulation of gene expression and drug
metabolism.244 Cell Host & Microbe 27, 238–248, February 12, 2020Modulation of AhR during Mycobacterial Infection and
Treatment In Vivo
We interrogated whether AhR-dependent RFB degradation af-
fects the efficacy of drug treatment in vivo. To this end, we
made use of the zebrafish-Mycobacterium marinum infection
model of mycobacterial pathogenesis (Van Leeuwen et al.,

























































































































Figure 6. AhR Modulation during M. marinum Infection and RFB Treatment In Vivo
(A) Cyp1a enzymatic activity (EROD) in 2 dpf embryos exposed to M. marinum for 24 h in E3 medium, in the presence or absence of 10 mM CH-223191. 1
representative of n = 3 independent experiments. Mean ± SD shown.
(B and C) Bacterial loads in zebrafish embryos at 4 d post-systemic infection with Wasabi-expressingM. marinum (200 CFU), untreated or treated with RFB for 3
d, in the presence or absence of 10 mM CH-223191. 1 representative of n = 2 independent experiments. Mean ± SEM shown.
(B) Representative micrographs.
(C) Quantification of Wasabi-expressing M. marinum pixels per whole embryo.
(A and C) Each data point depicts an individual zebrafish embryo, (C) while orange symbols indicate the individuals that were chosen as representative
micrograph. Unpaired t test. *p % 0.05, **p % 0.01, ****p % 0.0001.
See also Figures S7 and S8.M. marinum culture supernatants induced AhR activation
(Figure S7A), similar to Mtb and Mycobacterium bovis Bacillus
Calmette-Guérin (BCG; Moura-Alves et al., 2014). Exposure of
zebrafish embryos to M. marinum by immersion, a natural route
of infection (Dalton et al., 2017), induced Cyp1a enzymatic activ-
ity in zebrafish embryos, as did TCDD (Figures 6A and S7B).
Cyp1a enzymatic activation was abrogated by CH-223191 (Fig-
ure 6A). Our data support previous findings that mycobacterial
infection activates AhR signaling in other models, including
mouse (Moura-Alves et al., 2014). Hence, zebrafish represent a
suitable in vivomodel to study the role of the AhR during infection
and drug treatment.
Intravenous infection of zebrafish embryos with M. marinum
followed by AhR inhibition (CH-223191) resulted in higher bacte-
rial burden in embryos when compared with controls (Figures 6B
and 6C). This is in line with the increased bacterial burden
observed in AhR knockout mice infected withMtb (Moura-Alves
et al., 2014). Importantly, we did not identify any direct effect of
the specific AhR-inhibitor CH-223191 on bacterial growth or
fluorescence (Figures S8A–S8C), nor did we observe adjuvant
effects of CH-223191 during RFB treatment (Figures S8D and
S8E). Interestingly and in agreement with our in vitro results,
we observed a delay in macrophage phagocytosis of
M. marinum upon CH-233191 treatment in zebrafish embryos
in vivo (Figures S8F and S8G). Based on our results that suggest
a role for the AhR in RFB metabolism, we evaluated whether in-
hibition of the AhR inM.marinum-infected zebrafish embryos af-
fects efficacy of RFB treatment. Treatment with RFB dose
dependently decreased bacterial loads (Figures 6B and 6C),
confirming antimicrobial activity of RFB in M. marinum-infected
zebrafish embryos. Remarkably, AhR inhibition by CH-223191
enhanced RFB-mediated bacterial killing compared with AhR-
proficient controls (Figures 6B and 6C), correlating with higher
drug concentrations upon AhR inhibition (Figures 4B and 5F).
Of note, we did not observe AhR-dependent differences in bac-terial killing upon RIF treatment in zebrafish embryos as well as
changes in RIF metabolism upon AhR inhibition (Figures S8H
and S8I). Taken together, our data unveil that the AhR concom-
itantly senses infection and drug treatment, thereby playing a
central role in host-pathogen interactions and treatment in TB.
DISCUSSION
Here, we demonstrate that differential modulation of the AhR by
TB drugs influences both host defense and treatment outcome.
Hence, the AhR is a critical denominator in TB. More precisely,
we demonstrate that: (1) TB drugs, including the first-line drugs
RFB and RIF, are AhR ligands; (2) AhR modulation by both
RFB and RIF impairs macrophage phagocytosis and phagoso-
mal acidification; (3) RFB and RIF differentially regulate AhR
target gene expression and enzymatic Cyp1a activity in vitro
and in zebrafish; (4) inhibition of the AhR impairs metabolism of
RFB in human hepatocytes and in zebrafish; and (5) pharmaco-
logical inhibition of the AhR augments RFB-mediated antimicro-
bial activity in M. marinum-infected zebrafish embryos.
After aerogenic infection, macrophages are among the first
host cells to encounter Mtb (Gengenbacher and Kaufmann,
2012). We demonstrate that inhibition of the AhR affects phago-
cytosis of bothMtb and zymosan by a currently unknown mech-
anism. Previous studies showed an involvement of the AhR in
actin polymerization and cytoskeleton remodeling (Carvajal-
Gonzalez et al., 2009; Angeles-Floriano et al., 2016). Thus, it is
tempting to speculate that AhR-mediated regulation of this pro-
cess can potentially impact phagocytosis, although further
studies are needed to evaluate this hypothesis. Our findings
are reminiscent of a recent study reporting that AhR activation
by the opportunistic pathogenic yeast Candida albicans pro-
motes endocytosis by epithelial cells and that AhR inhibition re-
duces fungal invasion (Solis et al., 2017). Consistently, exposure
to the AhR ligands RFB and RIF likewise reduced macrophageCell Host & Microbe 27, 238–248, February 12, 2020 245
phagocytosis. Our observations are in agreement with earlier
studies reporting the effects of antibiotics on macrophage
phagocytosis (Nishida et al., 1976; Bode et al., 2014). We
conclude that impaired phagocytosis by TB drugs impacts
host defense and thereby influences therapy outcome. Because
of the vast spectrum of modulatory AhR ligands, this mechanism
should be taken into consideration for: (1) antibiotic treatment of
bacterial infections, in which phagocytosis plays a critical role,
such as TB; and (2) drug treatment in the presence of environ-
mental AhR modulators, which could affect host defense and
drug availability. Environmental risk factors for AhR modulation
may set a basal threshold, which affects diverse pathophysiolog-
ical pathways. For example, cigarette smoke contains several
potent AhR agonists, including TCDD (Muto and Takizawa,
1989) and benzo(a)pyrene (Stedman, 1968). The AhR has been
shown to regulate cigarette-smoke-induced cyclooxygenase-2
(COX-2) and prostaglandin E2 (PGE2) (Martey et al., 2005)
expression, the latter being critical in immunopathogenesis of
TB (Rangel Moreno et al., 2002). It is therefore tempting to envi-
sion that AhR signaling could participate in the heightened risk of
TB for smokers (Alcaide et al., 1996) and in their poor therapy
outcome (Leung et al., 2015; Yen et al., 2014).
The currently recommended treatment regimen of patients
with drug-susceptible TB consists of at least four drugs given
over an extended period of time (2-month intensive treatment
with INH, RIF, PZA, and EMB, followed by 4-month continuation
treatment with INH and RIF) (World Health Organization, 2017).
We identified TB drugs that modulate the AhR pathway in oppo-
site ways including RFB and RIF, which activated or inhibited
AhR, respectively. In combination therapy, this could result in
synergistic or antagonistic effects and thus should be taken
into consideration when formulating novel multidrug treatment
regimens for TB. The emergence of MDR- and XDR-TB has
become a global public health threat (World Health Organization,
2019). Treatment duration (Olofsson and Cars, 2007) and subop-
timal drug concentrations (DeRyke et al., 2006; Mitchison, 1998)
promote the development of AMR. Drug metabolism influences
duration and intensity of pharmacological action and is therefore
considered critical for AMR selection (Baquero et al., 1997; Negri
et al., 2000). Here, targeting the AhR by a specific small-mole-
cule inhibitor reduced the metabolism of RFB, resulting in
elevated drug concentrations and increased RFB-mediated anti-
microbial activity. We conclude that modulation of the AhR af-
fects overall drug availability and, potentially, the development
of AMR. Identification of suitable HDT targets is of vital impor-
tance to counteract the rising threat posed by AMR in TB. Given
the central role of the AhR in infection and treatment, we propose
the AhR as a candidate target for adjunct HDT in TB. Of note, tar-
geting the AhR has already been harnessed in other disease
models (Yeste et al., 2012, 2016; Zelante et al., 2013; Parks
et al., 2014; Cervantes-Barragan et al., 2017; Smith et al.,
2017; Lozza et al., 2019). However, because of its vast ligand
binding capacity (e.g., allowing sensing of both bacteria and
drug treatment) and its implication in multiple cellular and tissue
mechanisms, targeting the AhR might carry potential risks that
need to be further evaluated. The work presented here serves
as the foundation for future studies to ultimately verify the suit-
ability of the AhR as HDT in TB, looking at both potential benefits
and risks of such therapeutic intervention.246 Cell Host & Microbe 27, 238–248, February 12, 2020STAR+METHODS
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Ethambutol Sigma-Aldrich Cat#E4630; CAS#1070-11-7
Ethionamide Sigma-Aldrich Cat#E6005; CAS#536-33-4
Ethoxyresorufin Sigma-Aldrich Cat#E3763; CAS#5725-91-7
Hoechst 33342 Thermo Fisher Scientific Cat#62249
Hygromycin Sigma-Aldrich Cat#H3274; CAS#31282-04-9
Isoniazid Sigma-Aldrich Cat#I3377; CAS#54-85-3
Kanamycin Sigma-Aldrich Cat#60615; CAS#70560-51-9
Linezolid Sigma-Aldrich Cat#PZ0014; CAS#165800-03-3
Live Cell Imaging Solution Thermo Fisher Scientific Cat#A14291DJ
Moxifloxacin Sigma-Aldrich Cat#32477; CAS#186826-86-8
NucRed Live 647 ReadyProbesTM Reagent Thermo Fisher Scientific Cat#R37106
Polyvinylpyrrolidone, avg. mol wt. 40,000 (PVP40) Sigma-Aldrich Cat#PVP40
CAS#9003-39-8
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat#524400; CAS#16561-29-8
pHrodo Red Zymosan Bioparticles Conjugate Thermo Fisher Scientific Cat#P35364
Pronase Sigma-Aldrich Cat#PRON-RO
(Continued on next page)
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Puromycin Sigma-Aldrich Cat#P9620; CAS# 58-58-2
Pyrazinamide Sigma-Aldrich Cat#P4050000; CAS#98-96-4
Reporter Lysis Buffer Promega Cat#E4030
Rifabutin Carbosynth Cat#AR27727; CAS#72559-06-9
Rifampicin Sigma-Aldrich Cat#R3501; CAS#13292-46-1
Rifapentine Sigma-Aldrich Cat#R0533; CAS#61379-65-5
Streptomycin Sigma-Aldrich Cat#S6501; CAS#3810-74-0
SYBR green Thermo Fisher Scientific Cat#A25743
Thiacetazone Santa Cruz Biotechnology Cat#sc-358574; CAS#104-06-3
Critical Commercial Assays
Cytotoxicity Detection Kit (LDH) Roche Cat#11644793001
iScript cDNA Synthesis Kit Bio-Rad Cat#1708891
Luciferase Assay System Promega Cat#E1501
Pierce Coomassie Plus (Bradford) Assay Kit Thermo Fisher Scientific Cat#23236
RNeasy Mini Kit QIAGEN Cat#74106
Experimental Models: Cell Lines
Hepa-1c1c7 ATCC RRID: CVCL_0328; CRL-2026
THP-1 ATCC RRID: CVCL_0006;
TIB-202
THP-1 AhR reporter Moura-Alves et al., 2014 N/A
THP-1 AhR knockdown Moura-Alves et al., 2014 N/A
HepaRG Biopredic International HPR101
Experimental Models: Organisms/Strains
Zebrafish (Danio rerio) strain AB (wild-type line) EZRC ZFIN ID: ZDB-GENO-960809-7
Oligonucleotides
codon-optimized fragment of human AhR encoding amino
acid residues 23–475
This study N/A
ON-TARGET plus Human AHR (NM_001621) siRNA Dharmacon Code L-004990-00-0005
ON-TARGET plus Non-targeting Pool siRNA Dharmacon Code D-001810-10-05
Primers used for qRT-PCR, see Table S3 This study N/A
Recombinant DNA
pET21b Novagen Cat#69741
pET30-EK/LIC-mARNT expression plasmid encoding the
murine ARNT




GraphPad Prism, Version 7.0 GraphPad RRID: SCR_002798;
https://www.graphpad.com/










Maestro Suite, Version 11.8 Schrödinger RRID:SCR_016748;
https://www.schrodinger.com/maestro
NanoTemper Analysis software NanoTemper Technologies https://nanotempertech.com/monolith-mo-
control-software/
(Continued on next page)
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Photoshop CS5 Adobe RRID:SCR_014199;
https://www.adobe.com
PyMOL Molecular Graphics System, Version 1.8.4.1 Schrödinger RRID:SCR_000305;
https://pymol.org
Zebrafish Bacterial Load Analyzer software, Version 4 Nezhinsky et al., 2012 N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Pedro
Moura-Alves (pedro.mouraalves@ludwig.ox.ac.uk). Plasmids generated in this study will be made available upon request. There are
restrictions to the availability of HepaRG cells due to a material transfer agreement with Société Anonyme à Directoire et Conseil de
Surveillance (Inserm Transfert SA).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial Strains and Maintenance
Mycobacterium tuberculosis (Mtb) H37Rv, Mtb H37Rv-GFP and Mtb patient isolates (RIF-monoresistant isolate 18000790 or
drug-sensitive isolate 18000880, Forschungszentrum Borstel, Borstel, Germany) were cultured in Middlebrook 7H9 broth (BD) sup-
plemented with 0.05% Tween 80 (Sigma-Aldrich) and 10% albumin-dextrose-catalase (ADC, BD) at 37C in an orbital shacking incu-
bator at 100 rpm.MtbH37Rv-GFP was kept with additional 25 mg/mL kanamycin (Sigma-Aldrich).Mycobacteriummarinum E11 and
M strains were cultured in Middlebrook 7H9 broth (BD) supplemented with 0.05% Tween 80 (Sigma-Aldrich) and 10% oleic albumin-
dextrose-catalase (OADC, BD) statically at 30C protected from exposure to light.M. marinumM strain expressing pTEC15-Wasabi
(M. marinum-Wasabi; Takaki et al., 2013) was kept with additional 50 mg/mL hygromycin (Sigma-Aldrich).
Cell Culture and Maintenance
THP-1 cells (CVCL_0006, human monocytes, ATCC TIB-202), THP-1 AhR reporter (Moura-Alves et al., 2014) and THP-1 AhR knock-
down (Moura-Alves et al., 2014) cells were grown in RPMI 1640 (GIBCO), supplemented with 10% (v/v) heat-inactivated fetal calf
serum (FCS; GIBCO), 1% (v/v) sodium pyruvate (GIBCO), 1% (v/v) L-glutamine (GIBCO), 1% (v/v) non-essential amino acids
(MEMNEAA, GIBCO), 1% (v/v) 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, GIBCO) and 0.05 M 2-mercaptoethanol
(GIBCO). Hepa-1c1c7 cells (CVCL_0328, mouse hepatocytes, ATCC CRL-2026) were grown in DMEM (GIBCO) supplemented with
10% (v/v) FCS, 1% (v/v) sodium pyruvate and 1% (v/v) L-glutamine, 1% (v/v) HEPES. Undifferentiated HepaRG cells (human hepatic
progenitors, HPR101) were cultured in 710 growthmedium containing antibiotics and differentiated using 720 differentiation medium
containing antibiotics (all Biopredic International). AhR reporter cells were generated in accordancewith the protocols available at the
Genetic Perturbation Platform (GPP) of the Broad Institute (https://portals.broadinstitute.org/gpp/public/) as described previously
(Moura-Alves et al., 2014). In particular, a replication incompetent VSV-g pseudotyped lentivirus expressing the firefly luciferase
gene under transcriptional control of a minimal CMV promoter and tandem repeats of the XRE (Cignal Lenti XRE Reporter) was
used for infection of THP-1 cells. A similar protocol was used for the generation of AhR knockdown cells. Reporter cells and knock-
down cells were kept with additional 5 mg/mL puromycin (Calbiochem). THP-1 monocytes were differentiated into macrophages by
treatment with 200 nM of phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) for 4 d and rested in plain medium for another 4 d
before further experiments. For CYP1A1 enzymatic activity measurements (EROD; Mohammadi-Bardbori and Mohammadi-Bard-
bori, 2014), Hepa-1c1c7 cells were kept in DMEM medium without phenol red (GIBCO). HepaRG cells were cultured in 710 growth
medium for 2 weeks and subsequently differentiated by switching to 720 differentiation medium for another 2 weeks prior to exper-
iments according to the protocols by Biopredic International. All cells were kept in a humidified incubator (Heratherm, Thermo Fisher
Scientific) at 37C with 5% CO2. Sex of the cell lines was not a consideration in this study. Cell lines were obtained from authentic
stocks (ATCC and Biopredic International). If not specified otherwise in the figure legend, the highest concentration of DMSO used in
the experiments did not exceed 1%.
Zebrafish Model
All zebrafish (Danio rerio) husbandry and experimental procedures adhered to the international guidelines specified by the EU Animal
Protection Directive 2010/63/EU and experiments were approved by, and conducted in accordance with the guidelines of the
Landesamt f€ur Gesundheit und Soziales (LaGeSo, Berlin, Germany) and the animal welfare committee of the Max Planck Institute
for Infection Biology (MPIIB, Berlin, Germany). Only wildtype AB strain zebrafish (ZDB-GENO-960809-7) were used in this study.
Adult zebrafish used to generate embryos were housed in 3.5 L or 8 L tanks (Tecniplast) under the following water conditions:
28C; conductivity 500 mS (using Instant Ocean Sea Salt); pH 7.4-7.5. Zebrafish embryos were raised and maintained accordingCell Host & Microbe 27, 238–248.e1–e7, February 12, 2020 e3
to standard protocols (http://zfin.org). All zebrafish embryos used in this study were euthanized on or before 5 dpf. At these ages, sex
is indeterminate (Uchida et al., 2002; Liew and Orbán, 2014), hence no distinction between male and female was made.
Zebrafish embryos were maintained in E3 medium (5 mMNaCl, 0.17 mM KCl, 0.33 mMCaCl2, 0.33 mMMgSO4; N€usslein-Volhard
and Dahm, 2002) incubated at 28.5C in Petri dishes at amaximumdensity of 50 embryos per dish. To suppress fungal growth, meth-
ylene blue (2 mL of 0.1%methylene blue in 1l E3 medium) was added in experiments that did not involve microscopy. Embryos were
manually dechorionated at 1 dpf aided by a stereomicroscope (MZ6, Leica). Prior to experimental manipulations, zebrafish embryos
were anesthetized using buffered 3-aminobenzoic acid (Tricaine, MS-222, Sigma-Aldrich) at a final concentration of 200 mg/mL. For
experiments, embryos were pooled and randomly allocated to experimental groups. At the end of experiments, embryoswere eutha-
nized using an overdose of 300 mg/l Tricaine (Sigma-Aldrich).
METHOD DETAILS
Gene Expression Analysis by qRT-PCR
For the isolation of total RNA from cells, buffer RLT (QIAGEN) containing 1% 2-Mercaptoethanol (Sigma-Aldrich) was used. For the
isolation of total RNA from zebrafish embryos TRIzol (Invitrogen) was used. RNA extraction was performed using RNeasy PlusMini kit
(QIAGEN) according to the manufacturer’s instructions. RNA quality and concentration were determined by spectrophotometry
(Nanodrop 2000c, Thermo Fisher Scientific). Complementary DNA (cDNA) was generated using iScript cDNA synthesis kit (Biorad)
according to the manufacturer’s instructions. Quantitative real time polymerase chain reaction (qRT-PCR) was performed using Po-
wer SYBR green (Thermo Fisher Scientific) in a LightCycler 480 II PCR platform (Roche) running with LightCycler 480 Software
(SCR_012155, Version 1.5.1, Roche). The average threshold cycle of triplicate reactions was applied for all calculations and DDCt
method was used (Pfaffl, 2001). Gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
b-actin for human and zebrafish samples, respectively. qRT-PCR data were generated from independent experiments, with at least
3 biological replicates per experiment. Sequences of all primers used are listed in Table S3.
Luciferase Reporter Assay
AhR reporter cells were stimulated as depicted in figure legends. For competition assays, AhR reporter cells were pre-incubated with
TB drugs for 1 h prior to stimulation with 50 mMPht. After stimulation, cells were washed using sterile Dulbecco’s phosphate-buffered
saline (DPBS, GIBCO) and subsequently lysed using 1x concentrated Reporter Lysis Buffer (Promega). Cell lysates were used to
determine luciferase activity by Luciferase Assay System (Promega) according to the manufacturer’s instructions and luminescence
was measured with an Infinite M200 pro reader platform (TECAN). Luciferase activity was normalized to the protein concentration
measured by Bradford reaction (PierceTM Coomassie Plus Assay, Thermo Fisher Scientific). Results are shown as log2 fold induction
normalized to the solvent control of the respective time point.
siRNA Knockdown of AhR
THP-1 AhR reporter cells were treated with ON-TARGET plus siRNA AHR or ON-TARGETplus Non-targeting Pool (Dharmacon) for
24 h prior to stimulation with RFB, according to manufacturer’s instructions.
EROD Activity In Vitro
CYP1A1 is under transcriptional control of AhR (Nebert, Goujon andGielen, 1972; Poland, Glover and Kende, 1976; Poland and Knut-
son, 1982). The EROD assay measures the conversion of non-fluorescent ethoxyresorufin by CYP1A1 to the fluorescent product re-
sorufin, where the amount of resorufin-fluorescence is proportional to the enzymatic activity of CYP1A1 (Mohammadi-Bardbori and
Mohammadi-Bardbori, 2014). Cells were stimulated as depicted in the figures. After stimulation, cells were washed once using sterile
DPBS (GIBCO) and 5 mMethoxyresorufin (EROD, Sigma-Aldrich) and 10 mMdicoumarol (Sigma-Aldrich) were added to the cells for 1
h. Subsequently, relative fluorescence of resorufin (excitation 535nm/emission 590nm) was measured either in form of an endpoint
assay or as kinetic (kinetic reads every 30 min at 37C, 5% CO2) using an Infinite M200 pro reader platform (TECAN). EROD activity
was corrected to the protein concentration measured by Bradford reaction (PierceTM Coomassie Plus Assay, Thermo Fisher Scien-
tific) and normalized to the solvent control of the respective time point for end point assay. Endpoint assays are shown as Log2 ac-
tivity fold induction ans kinetic measurements are shown as total well fluorescence over time.
LDH Release Assay
Release of lactate dehydrogenase (LDH) was quantified using the Cytotoxicity Detection Kit PLUS (Roche) according to the manu-
facturer’s instructions. The percentage of cytotoxicity was calculated as:
Cytotoxicityð%Þ = exp erimental value low control
high control low control 3 100
Caspase-3/7 Activity Assay
Caspase activity wasmeasured using theCellEventTMCaspase-3/7 Green Detection Reagent (Thermo Fisher Scientific) according to
the manufacturer’s instructions. In particular, after stimulation cell nuclei were labeled using NucRedTM Live 647 ReadyProbesTMe4 Cell Host & Microbe 27, 238–248.e1–e7, February 12, 2020
Reagent (Thermo Fisher Scientific). Subsequently, cells were incubated with CellEventTM Caspase-3/7 Green Detection Reagent for
30 min and micrographs were acquired using an ArrayScanTM XTI High Content Analysis Reader (Thermo Fisher Scientific). For sub-
sequent analysis of Caspase-3/7 positive cells, nuclear labeling was used to identify and define cells and green fluorescence signal
was used to determine caspase-3/7 positive cells.
In Vitro Infections and Analysis
For in vitro infections,Mtb H37Rv,Mtb H37Rv-GFP orMtb patient isolates were cultured to an optical density at 600nm (OD600nm) of
0.5-0.8 and single-cell suspensions prepared by collecting bacterial culture supernatants after centrifugation at 120 x g for 10 min.
Bacterial CFU were calculated based on growth curves (OD600nm of 1 equals approximately 2.5 3 10
7 bacteria/mL). THP-1 macro-
phages were infected with cell culture medium containing a multiplicity of infection (MOI) of 10 for 4 h. After infection, bacteria not
internalized were removed by rigorous washing with sterile DPBS (GIBCO). For counting of CFU, cells were lysed using 0.1% Triton
X-100 (Sigma-Aldrich) in 1x DPBS (GIBCO) and serial dilutions were prepared in 0.04% Tween20 (Sigma-Aldrich) in 1x DPBS
(GIBCO). Bacterial dilutions were plated on Middlebrook 7H11 agar (BD) plates, sealed with parafilmM (Merck) and incubated at
37C for approximately 3 weeks. For the analysis of Mtb-GFP infected macrophages, cells were fixed using 4% paraformaldehyde
(PFA, Electron Microscopy Sciences) containing 1 mg/mL H33342 fluorescent DNA stain (Hoechst) in 1x DPBS (GIBCO) for 30 min at
4C and stored overnight in 2%PFA in 1x DPBS (GIBCO) at 4C.Micrographs were acquired using the ArrayScanTM XTI High Content
Analysis Reader (Thermo Fisher Scientific) and analysis was performed using the Cellomics Compartmental Analysis V4
BioApplication (Thermo Fisher Scientific) of the HCS Studio software (SCR_016787, Thermo Fisher Scientific).
Broth Dilution Assay
To determine the minimal inhibitory concentration (MIC) of RFB in the presence or absence of CH-223191 in axenic mycobacterial
cultures, we used the previously established broth dilution method (Wiegand, Hilpert and Hancock, 2008). Mtb H37Rv or
M. marinum-Wasabi were cultured to an OD600nm of 0.5-0.8 and subsequently diluted to an OD600nm of 0.1 in their respective culture
media. Cultures were diluted once more 1:50 in the respective culture medium and distributed to 96-well plates with round-bottom
(Thermo Fisher Scientific). Bacteria were then incubated with different concentrations of RFB in the presence or absence of 12 mM
CH-223191. After 7 d forMtb H37Rv and after 4 d forM. marinum cultures, 10ml resazurin dye (alamarBlueTM; Thermo Fisher Scien-
tific) was added to eachwell and incubated overnight. On the next day, supernatants were transferred to 96-well plates with clear flat-
bottom and absorbance was measured at 570nm using a GloMax Microplate Reader (Promega). Correction wavelength was
acquired at 600nm. MICs were determined by comparing the absorbance to culture negative background controls.
Zymosan-pHrodo Phagocytosis Assays
Zymosan is a protein-carbohydrate complex extracted from the cell wall of the yeast S. cerevisiae. We used zymosan conjugated to
pHrodo (Thermo Fisher Scientific), a pH-sensitive fluorescent dye that increases its brightness in acidic environments. THP-1 mac-
rophages were pre-stimulated with different compounds as depicted in figure legends. After stimulation, supernatants were removed
and cells incubated with 0.5 mg/mL pHrodo Red zymosan A BioParticles conjugate (Thermo Fisher Scientific) in 1 x Live Cell Imaging
Solution (Thermo Fisher Scientific) for 2 h. Cells were washed rigorously with 1x DPBS and fixed with 2% PFA containing 1 mg/mL
H33342 fluorescent DNA stain (Hoechst) in 1x DPBS (GIBCO) for 30 min at 4C, protected from exposure to light. Micrographs were
acquired using the ArrayScanTM XTI High Content Analysis Reader (Thermo Fisher Scientific) and analysis was performed using the
CellomicsCompartmental Analysis V4 BioApplication (Thermo Fisher Scientific) of the HCS Studio software (SCR_016787, Thermo
Fisher Scientific). Results are shown as mean of total pHrodo zymosan fluorescence intensity per cell of a 40 field acquisition area
acquired with a 20x objective.
Rifabutin Metabolism
Differentiated HepaRG cells or 2 dpf zebrafish embryos were stimulated with 10mM RFB in the culture medium or zebrafish water,
respectively. At different time points, supernatants or fish water were collected and used for analysis by ultra-performance liquid
chromatography (UPLC). RFB was extracted by adding chloroform/methanol (2:1). After mixing and centrifugation, the organic lower
phase was collected and evaporated in a vacuum concentrator. Dried samples were dissolved in 50% methanol, 0.1% formic acid.
Subsequently, the RFB extracts were loaded onto anHSSC18 reversed phaseUPLC column. RFBwas elutedwith a linear gradient of
15% acetonitrile to 90% acetonitrile (containing 0.1% formic acid) over 5 min at 45C and a flow rate of 0.6 mL/min. Eluted com-
pounds were detected by UV absorbance and by ESI-MS detection. RFB was detected by single ion recording (SIR) of m/z
847.5. The ESI-MS detection was operated in an electrospray positive ion mode with a voltage of 0.8 kV, a cone voltage of 15 V
and a probe temperature of 600C. A full mass spectrum between m/z 100 and m/z 1200 was acquired at a sampling rate of 8.0
points/sec. Quantification of RFB was performed by integration of the UV-absorbance peak at 360nm based on a seven point cali-
bration from 1 pmol to 500 pmol of RFB.
Molecular Modeling
First, the conformational space of RFB and RIF was analyzed with the conformational search tool of Maestro (SCR_016748, Version
11.8, Schroedinger), carried out with standard settings as mixed torsional / low-mode sampling. 122 different conformations were
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monomer model of PasB-hAhR (Moura-Alves et al., 2014), utilizing the induced fit docking method of Maestro (SCR_016748, Version
11.8, Schroedinger). Amine bonds of the ligands were allowed to vary in conformation and the ring conformations were sampled with
an energy window of 6 kcal/mol. To allow for more room in the binding pocket, during the induced fit procedure several side chains
covering the binding pocket of AhR (RFB: residues H291, F295, C300, M340, M348, F351; RIF: F287, T289, H291, F295, L308, Y322,
Y322, I325, C333, M340, M348, F351, L353, V363, S365, I379, V381) were substituted with alanine (trimmed) in the initial docking
step. In the second step these trimmed residues were reconstituted and refined together with amino acids located 5.0 Å around
the initial ligand pose before the Glide re-docking (third step). The binding energy of the different molecules (DG binding) was calcu-
lated using the Prime MM-GBSA tool of Maestro (SCR_016748, Version 11.8, Schroedinger). Heterodimer models of hAhR and Arnt
each comprising HLH / PasA / PasB domains were generated based on crystal structures on one hand of the homologous Hif2a
/ARNT complex (Wu et al., 2015) including dynamic studies thereof (Motta et al., 2018) and on the other hand of the CLOCK/
Bmal1 complex (Huang et al., 2012). Structural images were generated with PyMOL Molecular Graphics System (SCR_000305,
Version 1.8.4.1, Schroedinger)
AhR Binding Studies Using MST
A codon-optimized fragment of human AhR encoding amino acid residues 23–475 was commercially synthesized (MWG Eurofins)
and cloned into pET21b (Novagen) using NcoI and XhoI restriction sites. The pET30-EK/LIC-mArnt expression plasmid encoding
the murine Arnt (residues 85-465) was a kind gift from Oliver Daumke (MDC Berlin). For protein expression, BL21(DE3) cells were
co-transformed with both plasmids. Bacteria were grown to OD600nm of 0.6 in LB medium and protein expression was induced
with 0.5 mM isopropyl-b-D-thiogalactopyranoside (IPTG), followed by overnight expression at 18C. Proteins were purified as pre-
viously described (Huang et al., 2012). Specifically, cell pellets were resuspended in lysis buffer containing DNaseI (Serva) and Com-
plete Protein Inhibitor Cocktail (Roche) and lysed using a French Press. The clarified lysate was applied onto a HisTALON Superflow
column (Clontech) and bound protein was elutedwith increasing concentrations ofimidazole. Elution fractionswere buffer exchanged
and N-terminal 6xHis-tags were removed with PreScission protease overnight at 4C. Cleaved protein complex was further purified
on a HiTrap Heparin HP column (GE Healthcare), followed by SEC on a Superdex 200 10/300 GL equilibrated in 20 mM HEPES pH
8.0, 200 mM NaCl, 5% glycerol, and 5 mM DTT. Peak fractions containing AhR-Arnt were pooled and concentrated using Amicon
filter units (Millipore).
Binding studies using purified AhR-Arnt complex were performed by microscale thermophoresis (MST) using the Monolith
NT.LabelFree (NanoTemper Technologies GmbH). MST measurements were performed according to the manufacturer’s instruc-
tions. In particular, a constant protein concentration of 250 nM diluted in assay buffer including 0.1% Pluronic F-127 was used.
To this, a serial dilution of ligand dissolved in DMSO was added. After short incubation, samples were filled into NT LabelFree
Zero Background MST Premium coated capillaries (NanoTemper Technologies GmbH). Measurements were carried out at 22C.
MST traces were collected with an LED excitation power of 20% and a MST laser power of 20%–40%. For analyzing the interaction
affinity, the dissociation constant (Kd) for each ligand was calculated using the NanoTemper Analysis software by plotting changes in
the normalized fluorescence (DFnorm [&]) as a function of the ligand concentration.
Zebrafish Chemical Stimulations
In stimulation experiments, 2 dpf embryos were treated with different compounds in E3 medium for the durations indicated in the
respective figures. In experiments using the AhR inhibitor CH-223191 (Sigma-Aldrich), embryos were pre-exposed to 10 mM CH-
223191 in E3 for 2 h prior to the experiment and the inhibitor was present during the entire duration of the experiment.
Zebrafish Cyp1a Enzymatic Activity
EROD experiments were conducted as previously described (Nacci et al., 1998). In detail, during the assay non-fluorescent 7-ethox-
yresorufin diffuses into the embryo where it is converted by Cyp1a to the fluorescent product resorufin. After compound stimulation
or immersion with M. marinum, 2 dpf zebrafish embryos were washed and placed in E3 medium containing 0.4 mg/mL of 7-ethox-
yresorufin (Cayman Chemical) for 5 min. After incubation, embryos were anesthetized with 200 mg/mL tricaine (MS-222, Sigma-Al-
drich) and placed in black 96-well plates with clear bottom (Thermo Fisher Scientific) and micrographs were acquired using the
ArrayScanTM XTI High Content Analysis Reader (Thermo Fisher Scientific). Brightfield images were used to identify embryo outlines
and embryo fluorescence (filters excitation: 549/15nm, emission: 590-624nm) was determined as a readout of Cyp1a activation using
the Cellomics Zebratox BioApplication (Thermo Scientific) of the HCS Studio software (SCR_016787, Thermo Fisher Scientific).
Zebrafish Toxicity
For the assessment of compound toxicity for zebrafish embryos, brightfield images were acquired using the ArrayScanTM XTI High
Content Analysis Reader (Thermo Fisher Scientific). To evaluate toxicity, the Cellomics Zebratox BioApplication (Thermo Fisher
Scientific) of the HCS Studio software (SCR_016787, Thermo Fisher Scientific) was used. Head-to-tail distance and embryo straight-
ness served as measure for compound toxicity.
Zebrafish Infection
In infection by immersion experiments, 2 dpf embryos were placed in E3 medium inoculated with different concentrations of
M. marinum E11 and incubated at 28C for time of the experiment. Inoculum preparations and infection by intravenous injectione6 Cell Host & Microbe 27, 238–248.e1–e7, February 12, 2020
of zebrafish embryos were performed as described (Benard et al., 2012). In particular, a colony of M. marinum-Wasabi was resus-
pended in 10mLMiddlebrook 7H9 broth (BD) containing 10%ADC (BD), 0.05%Tween 80 (Sigma-Aldrich) and 50 mg/mL hygromycin
(Sigma-Aldrich). The culture was set to an OD600nm of 0.2-0.3 and cultured statically overnight at 28
C. On the day of infection, OD
was measured again to ensure the logarithmic growth phase of the culture and bacteria were harvested by centrifuging and washing
3 times in sterile 1x PBS. Based on previous growth curves, an OD600nm of 1 corresponded to approximately 10
8M.marinum/mL and
was used to determine CFU for infection. Bacteria were centrifuged and resuspended in 2% polyvinylpyrrolidone (PVP40, Sigma-Al-
drich) in PBS (w/v) to the desired concentration. Before infection, zebrafish embryos were staged at 28 hpf based on morphological
criteria. Anesthesia was induced using 200 mg/mL tricaine (MS-222, Sigma-Aldrich) approximately 10 min prior to infection. Borosil-
icate glass microcapillaries (Science Products GmbH BF100-78-10, with filament) were loaded with the bacterial inoculum using a
microloader tip and subsequently mounted to a micromanipulator (Sutter Instrument, MM-33) with stand (World precision Instru-
ments, M10L magnetic stand). Injections were performed using a FemtoJet microinjector (Eppendorf) under a Leica M50 stereomi-
croscope (Leica). Anesthetized embryos were positioned on a flat 1% agarose plate and a scale bar was used to determine the
desired injection volume of approximately 1 nL/embryo. 200 CFU Wasabi-expressing M. marinum were injected into the caudal
vein of a single embryo. After infection embryos were rested for 30 min in E3 medium at 28C.
RFB Treatment of M. marinum-Infected Zebrafish
Infected zebrafish embryos were pooled and randomly distributed into different experimental groups. Embryos were incubated in
either 10 mM CH-223191 or DMSO at 28C for 2 h. Subsequently, embryos were treated once with either 5 mM or 10 mM RFB, or
with DMSO as untreated control. Treatment was applied by adding RFB directly to the medium. At 4 d post infection (dpi), embryos
were anesthetized and imaged using a stereomicroscope (MZ16FA, Leica) equipped with a DFC3000Gdigital color camera (Leica).
Brightfield and fluorescence stereomicroscopy overlays were created using Adobe Photoshop (SCR_014199, Photoshop CS5,
Adobe). To quantify the amount of fluorescent bacteria, bacterial pixel counts were determined and analyzed using Zebrafish Bac-
terial Load Analyzer software (Version 4, A. Nezhinsky, University Leiden Institute of Advanced Computer Science, Leiden, the
Netherlands).
QUANTIFICATION AND STATISTICAL ANALYSIS
For in vivo experiments, zebrafish embryos were randomly assigned to different experimental groups and group size was chosen to
allow a significance threshold a of 0.05 with a power of 80% (b = 0.2). For in vitro experiments, cells were randomly distributed in
different culture well plate positions. All statistical details of experiments can be found in the figure legends. Data are presented
as mean ± SD (for individual experiments) or as mean ± SEM (for pooled experiments), as described in figure legends. To compute
P values, unpaired t test or Mann-Whitney test was used, as described in figure legends. GraphPad Prism (SCR_002798, version 7.0,
GraphPad) was used for analysis and differences were considered statistically significant at p % 0.05.
DATA AND CODE AVAILABILITY
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